Answers are grounded in this paper and cite their sources.
Diabetic macular edema (DME) requires frequent intravitreal anti-VEGF injections, creating substantial treatment burden. Navigated laser photocoagulation offers precise microaneurysm targeting, but its adjunctive benefit with anti-VEGF therapy remains inadequately documented in real-world settings. This retrospective comparative study included 87 treatment-naive DME patients followed for 24 months. Group A (n = 42) received intravitreal bevacizumab monotherapy; Group B (n = 45) received combination therapy (bevacizumab plus Navilas navigated laser photocoagulation). Primary endpoints were injection burden, recurrence rates, and hyperreflective dot (HRD) count as an inflammatory biomarker on spectral-domain optical coherence tomography. Combination therapy required significantly fewer injections over 24 months (4.6 ± 1.8 vs. 7.3 ± 2.1; p < 0.001), representing 37% reduction. Recurrence rates were lower in the combination group (17.8% vs. 33.3%; p = 0.03). Kaplan-Meier analysis showed significantly prolonged recurrence-free survival in the combination group (log-rank p = 0.016), with 24-month recurrence-free survival of 82.2% versus 66.7%. HRD reduction was superior with combination therapy (61% vs. 28%; p = 0.01). Baseline HRD count correlated with injection frequency (r=-0.54; p < 0.001) and recurrence risk (r = 0.48; p = 0.002). Visual acuity gains and central retinal thickness reductions were equivalent between groups. No serious adverse events occurred; 8.9% required repeat laser. Navigated laser photocoagulation combined with bevacizumab significantly reduces injection burden and recurrence in DME while maintaining efficacy, offering a more sustainable treatment approach. HRD count emerged as a clinically accessible biomarker for treatment planning.
No takes yet. Share an insight, caveat, or question.
Korkmaz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: